Explore 3 Stock Ideas & Industry Insights Download Free Report
ImmuPharma Plc — LSE:IMM gained7.07% on 14 August 2026, bringing renewed attention to the UK-listed specialist drug-development company.
Genflow Biosciences PLC — LSE:GENF has attracted renewed investor attention after gaining9.74% on 14 August 2026.
Coiled Therapeutics Plc — LSE:COIL gained5.56% on 14 August 2026, bringing renewed attention to the newly restructured clinical-stage biotechnology company.
Verici Dx PLC LSE:VRCI has come sharply into focus after its shares fell16.00% on 14 August 2026.
Futura Medical PLC LSE:FUM has come sharply into focus after its shares fell15.91% on 14 August 2026.
Proteome Sciences LSE:PRM gained8.89% on 14 August 2026, bringing renewed attention to a specialist UK healthcare company operating in the rapidly evolving field of proteomics.
HemoGenyx Pharmaceuticals develops treatments for blood cancers, autoimmune disorders and other serious diseases. Investor sentiment has improved as HG-CT-1 advances through clinical development and the company establishesManufacturingand commercial infrastructure. The stock’s rise also reflects renewed interest in differentiated oncology platforms, particularly therapies addressing diseases …
Hemogenyx Pharmaceuticals is a clinical-stage biopharmaceutical company developing treatments for blood cancers, bone-marrow disorders, autoimmune conditions and severe viral diseases. Investor interest has recently improved following progress in its lead HG-CT-1 programme and the conversion of an earlier non-binding arrangement with Cellin Technologies into …
Arecor Therapeutics Plc is a biopharmaceutical company developing next-generation formulations of established therapeutic proteins, including ultra-rapid-acting insulin products, using its proprietary formulation technology. The shares advanced in the latest session, a move consistent with renewed investor interest in specialist biopharmaceutical formulation companies.
Oxford Nanopore Technologies PLC (LSE:ONT) shares fell to 124.90p, down 1.20p, or 0.95%, according to the market data provided, easing back after a period of recent momentum for the genomics technology company.
We use some essential cookies to make this site work. We also set analytics and marketing cookies, described below, to understand how you use the site and to measure our advertising. For more detailed information, see our Cookie Policy, Privacy Policy and Terms and Conditions.
These cookies are necessary for core functionality, such as security, your shopping cart, remembering your cookie choice, and your progress through a report or free-trial request you started. They always need to be on.
We use analytics cookies to understand how visitors use the site — the pages visited, time spent, and where visitors came from.
These help us measure how effective our advertising is, such as recording actions you take after clicking one of our ads. If you don't enable this, you may still see our ads, but they won't be measured this way.
Please wait processing your request...
You are not subscribed for this report, Want to See?
One of our sales representative will contact you soon!
Welcome to Kalkine!
Download Free Report
Hi! How can we help you today?
Loading…